Jacobs Levy Equity Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
Other funds holding OREX
TI
Jacobs Levy Equity Management's OREX Position: Q1 2018 in Review
Jacobs Levy Equity Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2018, closing a stake of 133,658 shares — an estimated $172K sold.
Jacobs Levy Equity Management first reported a position in OREX in Q1 2017 and held it in 3 quarters. The position peaked at $194K in Q3 2017. 27 funds tracked by Wall St. Rank hold OREX as of Q1 2018.
- Jacobs Levy Equity Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Jacobs Levy Equity Management sold 133,658 Orexigen Therapeutics, Inc. shares in Q1 2018, an estimated $172K.
- Jacobs Levy Equity Management first reported a position in Orexigen Therapeutics, Inc. in Q1 2017 and held it in 3 quarters.
- Jacobs Levy Equity Management's Orexigen Therapeutics, Inc. position peaked at $194K in Q3 2017.
- 27 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2018.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2018, filed 15 May 2018.